IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) had its price target upped by stock analysts at Royal Bank of Canada from $36.00 to $43.00 in a report released on Wednesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank of Canada’s price target suggests a potential upside of 16.44% from the stock’s current price.
Other research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. raised their price target on shares of IDEAYA Biosciences from $35.00 to $41.00 and gave the company an “overweight” rating in a report on Thursday, November 30th. The Goldman Sachs Group boosted their price target on IDEAYA Biosciences from $31.00 to $37.00 and gave the stock a “buy” rating in a research report on Tuesday, September 12th. Wedbush reissued an “outperform” rating and issued a $43.00 price objective on shares of IDEAYA Biosciences in a research note on Wednesday, November 8th. Finally, Guggenheim reduced their target price on IDEAYA Biosciences from $48.00 to $44.00 and set a “buy” rating for the company in a report on Wednesday, November 8th. Eleven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $35.27.
View Our Latest Research Report on IDYA
IDEAYA Biosciences Price Performance
Shares of NASDAQ IDYA opened at $36.93 on Wednesday. IDEAYA Biosciences has a one year low of $13.29 and a one year high of $37.25. The business’s 50-day moving average price is $32.61 and its two-hundred day moving average price is $28.02. The company has a market capitalization of $2.38 billion, a P/E ratio of -18.94 and a beta of 0.82.
IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last announced its quarterly earnings results on Tuesday, November 7th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.03. The business had revenue of $8.00 million during the quarter, compared to analysts’ expectations of $8.14 million. IDEAYA Biosciences had a negative return on equity of 24.39% and a negative net margin of 439.48%. The company’s revenue was up 128.6% on a year-over-year basis. On average, equities analysts anticipate that IDEAYA Biosciences will post -1.95 EPS for the current year.
Insider Buying and Selling
In other IDEAYA Biosciences news, insider Jason Throne sold 5,163 shares of the firm’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $30.09, for a total value of $155,354.67. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other IDEAYA Biosciences news, insider Jason Throne sold 5,163 shares of the company’s stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $30.09, for a total value of $155,354.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Yujiro S. Hata sold 75,000 shares of IDEAYA Biosciences stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $35.03, for a total value of $2,627,250.00. Following the sale, the chief executive officer now directly owns 677,887 shares in the company, valued at approximately $23,746,381.61. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 82,163 shares of company stock valued at $2,850,605. 5.00% of the stock is owned by company insiders.
Hedge Funds Weigh In On IDEAYA Biosciences
A number of hedge funds have recently made changes to their positions in the business. Exchange Traded Concepts LLC increased its stake in IDEAYA Biosciences by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 4,806 shares of the company’s stock valued at $171,000 after acquiring an additional 1,219 shares during the period. Vanguard Group Inc. grew its stake in shares of IDEAYA Biosciences by 5.0% in the 3rd quarter. Vanguard Group Inc. now owns 2,971,497 shares of the company’s stock valued at $80,171,000 after purchasing an additional 141,844 shares during the period. Hudson Bay Capital Management LP acquired a new position in shares of IDEAYA Biosciences in the 3rd quarter worth approximately $944,000. Citigroup Inc. lifted its position in shares of IDEAYA Biosciences by 3.7% during the 3rd quarter. Citigroup Inc. now owns 55,254 shares of the company’s stock worth $1,491,000 after buying an additional 1,967 shares during the period. Finally, American Century Companies Inc. boosted its stake in IDEAYA Biosciences by 36.7% in the 3rd quarter. American Century Companies Inc. now owns 39,655 shares of the company’s stock valued at $1,070,000 after buying an additional 10,640 shares in the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.
IDEAYA Biosciences Company Profile
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company’s lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase II clinical trial for patients with solid tumors having methylthioadenosine phosphorylase gene deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.
Further Reading
Receive News & Ratings for IDEAYA Biosciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for IDEAYA Biosciences and related companies with MarketBeat.com’s FREE daily email newsletter.